Action ARROWHEAD RESEARCH CORP
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues Arrowhead Research Corp Nasdaq

Actions

US0427972098

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Arrowhead Nets $50 Milestone Payment from Royalty Pharma After Completion of Enrollment in Trial of Cardiovascular Drug
Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
Arrowhead Pharmaceuticals, Inc. Initiates Expanded Access Program for Plozasiran
Arrowhead Doses First Subjects in Phase 1/2a Study of Myotonic Dystrophy Treatment; Shares Rise
Arrowhead Pharmaceuticals : 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference View Presentation
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
Certain Restricted Stock Units of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-MAR-2024.
Certain Common Stock of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-MAR-2024.
Arrowhead Pharmaceuticals, Inc. Appoints Hongbo Lu as Independent Director, Effective April 1, 2024
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ARWR
  4. Action
  5. Actualités Arrowhead Research Corp
  6. Autres langues